Theranostics
2019; 9(16):4595-4596.
doi:10.7150/thno.36746 This issue
Erratum
Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting: Erratum
Maximilian Klingler1, Clemens Decristoforo1, Christine Rangger1, Dominik Summer1, Julie Foster2, Jane K Sosabowski2, Elisabeth von Guggenberg1✉
1. Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria
2. Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Klingler M, Decristoforo C, Rangger C, Summer D, Foster J, Sosabowski JK, von Guggenberg E. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting: Erratum.
Theranostics 2019; 9(16):4595-4596. doi:10.7150/thno.36746. Available from
https://www.thno.org/v09p4595.htm
Corrected-article in Theranostics, Volume 8, 2896